News tagged with clopidogrel
The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs – prasugrel and clopidogrel – in preventing ...
Cardiology Aug 26, 2012 | not rated yet | 0 |
Researchers study under-recognised and under-treated prothrombotic condition: High platelet reactivity despite treatment
Within the past decade, the variability in pharmacodynamic response and moderate antiplatelet efficacy of clopidogrel has raised major concerns, in particular because it is associated with an increased risk for ischemic events ...
Cardiology May 06, 2013 | not rated yet | 0
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular ...
Cardiology Aug 27, 2012 | not rated yet | 0
(HealthDay) -- Aspirin works as well as Plavix in patients with blocked leg arteries, a new European study finds.
Cardiology Feb 22, 2012 | 5 / 5 (1) | 1
(Medical Xpress)—An experimental drug has been shown to be significantly more effective at preventing blood clots during coronary stenting procedures compared to the anti-clotting agent now typically used, according to ...
Cardiology Mar 11, 2013 | not rated yet | 0 |
(HealthDay)—A full year of aggressive anti-clotting therapy—which can lead to heavy bleeding—may not be needed after surgery to implant a drug-coated cardiac stent, two new studies suggest.
Cardiology Sep 20, 2012 | not rated yet | 0 |
(HealthDay)—In the search for better medicines to safely help heart patients, clinical trials testing three new drugs appear to offer some promise.
Cardiology Mar 11, 2013 | 4 / 5 (1) | 0
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent ...
Cardiology Mar 11, 2013 | not rated yet | 0
Complications in patients undergoing percutaneous coronary intervention tend to occur within first 30 days
Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a ...
Cardiology Mar 24, 2012 | not rated yet | 0 |
Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.
Cardiology Mar 13, 2013 | not rated yet | 0 |
Allergies to Plavix, also know by its chemical name, Clopidogrel occur in about six percent of patients given the drug, vital for the prevention of life-threatening stent thrombosis after angioplasty and percutaneous coronary ...
Medications Jan 16, 2012 | not rated yet | 0
(HealthDay)—Prehospital use of antiplatelet therapy, either aspirin/clopidogrel or dual antiplatelet therapy (DAPT), is associated with a lower incidence of major adverse cardiac events after saphenous ...
Cardiology Jan 28, 2013 | not rated yet | 0
(HealthDay)—Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue ...
Diabetes Sep 05, 2012 | not rated yet | 0
(HealthDay) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.
Medications May 15, 2012 | not rated yet | 0
Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding, ...
Cardiology Aug 29, 2012 | not rated yet | 0 |
Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate ADP chemoreceptor. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).
For more information about Clopidogrel, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.